Advertisement

Myeloproliferative Neoplasms and Mastocytosis

  • Luke R. Shier
  • Tracy I. GeorgeEmail author
Chapter
Part of the Atlas of Anatomic Pathology book series (AAP)

Abstract

This chapter covers the myeloproliferative neoplasms (MPNs) and mastocytosis. The MPNs are clonal neoplasms characterized by increased bone marrow cellularity, organomegaly, and increased effective cellular maturation resulting in elevated blood levels of one or more cell lines (erythrocytosis, leukocytosis, thrombocytosis). Though dysplasia is typically absent, the MPNs can evolve into acute leukemia or an end-stage myelofibrosis. The disease course is typically long, developing over many years. A common theme of tyrosine kinase activation unites the MPNs, including mastocytosis. There is considerable overlap of clinical, laboratory, and pathologic features for many of these neoplasms; over time, one type of MPN may develop features of another. Figures and tables willillustrate the bone marrow pathology of the MPNs and mast cell disease, including relevant clinical, laboratory, cytogenetic, and molecular genetic findings

Keywords

BCR-ABL1 CALR CSF3R MPL JAK2 Chronic myeloid leukemia Essential thrombocythemia Polycythemia vera Primary myelofibrosis Mastocytosis Chronic eosinophilic leukemia, not otherwise specified Chronic neutrophilic leukemia Myeloproliferative neoplasm, unclassifiable 

References

  1. 1.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMedGoogle Scholar
  2. 2.
    Horny H-P, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, Valent P. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. p. 54–63.Google Scholar
  3. 3.
    Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017. [Epub ahead of print].  https://doi.org/10.1182/blood-2017-01-761999.
  4. 4.
    Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.PubMedGoogle Scholar
  5. 5.
    Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis – a consensus-based study. Histopathology. 2016;68:905–15.CrossRefPubMedGoogle Scholar
  6. 6.
    Arredondo AR, Gotlib J, Shier L, Medeiros B, Wong K, Cherry A, et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 2010;85:600–6.CrossRefPubMedGoogle Scholar

Suggested Reading

  1. Chabot-Richards D, Shier LR, George TI. Pathology of the myeloproliferative neoplasms. In: Greer JP, Appelbaum F, Arber DA, Dispenzieri A, Fehniger T, Glader B, et al., editors. Wintrobe’s clinical hematology. 14th ed. (in press) ed. Philadelphia: Lippincott Williams and Wilkins; 2017.Google Scholar
  2. George TI, Sotlar K, Valent P, Horny H-P. Mastocytosis. In: Jaffe ES, Arber DA, Harris NL, Quintanilla-Martinez L, editors. Hematopathology. 2nd ed. Philadelphia: Elsevier; 2017. p. 911–30.Google Scholar
  3. Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013;122:1707–11.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129:704–14.CrossRefPubMedGoogle Scholar
  5. Wang SA, Tam W, Tsai A, Arber DA, Hasserjian RP, Geyer JT, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016;29:854–64.CrossRefPubMedGoogle Scholar
  6. Wang SA, Hasserjian RP, Tam W, Tsai AG, Geyer JT, George TI, et al. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified from reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017. [Epub ahead of print].  https://doi.org/10.3324/haematol.2017.165340.

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineUniversity of OttawaOttawaCanada
  2. 2.Department of PathologyUniversity of New Mexico School of MedicineAlbuquerqueUSA

Personalised recommendations